SWShengye Wang

Shengye Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shengye Wang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Binbing Wang

    Zhejiang Cancer Hospital, Hangzhou, China

    1 shared publication
  • Guoping Shan

    Chinese Acad Sci, Inst Basic Med & Canc IBMC, Zhejiang Canc Hosp, Dept Radiat Phys,Canc Hosp,Univ Chinese Acad Sci, Hangzhou 310022, Zhejiang, Peoples R China

    1 shared publication
  • Hongying Luo

    Univ South China, Sch Nucl Sci & Technol, Hengyang 421001, Hunan, Peoples R China

    1 shared publication
  • Jianliang Zhou

    Univ South China, Sch Nucl Sci & Technol, Hengyang 421001, Hunan, Peoples R China

    1 shared publication
  • Jianlin Lou

    Chinese Acad Sci, Inst Basic Med & Canc IBMC, Zhejiang Canc Hosp, Dept Head & Neck Surg,Canc Hosp,Univ Chinese Acad, Hangzhou 310022, Zhejiang, Peoples R China

    1 shared publication
  • Jie Zhang

    Department of Radiation Physics Zhejiang Cancer Hospital Hangzhou Zhejiang China

    1 shared publication

Latest Publications

    • 15 November 2022
      • Vol. 14  (11) , 7985-7993

    Dosimetric advantages of robust optimization combined with flattening filter free in treating cancer of the left breast

    by Hongying Luo, Jianlin Lou, Wei Feng, Guoping Shan, Kainan Shao, Yiwei Yang, Jianliang Zhou, Shengyu Wang

    Objective: By comparing the target dose distribution with or without the robust optimization, the dosimetric advantages of robust optimization and flattening filter free (FFF) in radiation therapy for postmastectomy cancer of the left breast was explored when part of the chest wall target was moved out in case of respiratory motion. Materials and methods: This is a retrospective study. The data of 21 postmastectomy patients with cancer of the left breast from 2019 to 2020 were retrospectively collected. The planned target volume (PTV) dose was prescribed 50 Gy/25 fractions and the treatment plans were designed using 6 MV FFF X ray and volumetric modulated arc therapy (VMAT) technology in RayStation treatment planning system (TPS), with and without robust optimization. The movement of the target area of the internal chest wall (0.50 cm) caused by respiratory movement was simulated by moving the isocenter of the beams. Results: When the chest wall target moved outward, the PTV target area D-98, D-95, D-2, conformity index (CI) and homogeneity index (HI) with robust optimization were better than those without robust optimization. The coverage rate of Planned Target Volume-Chest (PTV-T) V-50 with robust optimization was significantly higher than that with no-robust optimization (P0.05). Conclusions: Robust optimization could be adopted in the postoperative radiotherapy planning for cancer in the left breast, for it ensures that the target dose coverage and the dose limit of organ-at-risk still meet the clinical requirements under condition of chest wall displacement caused by respiratory movement.


  • Open Access

    Sharp loss: a new loss function for radiotherapy dose prediction based on fully convolutional networks

    by Xue Bai, Jie Zhang, Binbing Wang, Shengye Wang, Yida Xiang, Qing Hou

    Background: Neural-network methods have been widely used for the prediction of dose distributions in radiotherapy. However, the prediction accuracy of existing methods may be degraded by the problem of dose imbalance. In this work, a new loss function is proposed to alleviate the dose imbalance and achieve more accurate prediction results. The U-Net architecture was employed to build a prediction model. Our study involved a total of 110 patients with left-breast cancer, who were previously treated by volumetric-modulated arc radiotherapy. The patient dataset was divided into training and test subsets of 100 and 10 cases, respectively. We proposed a novel ‘sharp loss’ function, and a parameter γ was used to adjust the loss properties. The mean square error (MSE) loss and the sharp loss with different γ values were tested and compared using the Wilcoxon signed-rank test. Results: The sharp loss achieved superior dose prediction results compared to those of the MSE loss. The best performance with the MSE loss and the sharp loss was obtained when the parameter γ was set to 100. Specifically, the mean absolute difference values for the planning target volume were 318.87 ± 30.23 for the MSE loss versus 144.15 ± 16.27 for the sharp loss with γ = 100 (p < 0.05). The corresponding values for the ipsilateral lung, the heart, the contralateral lung, and the spinal cord were 278.99 ± 51.68 versus 198.75 ± 61.38 (p < 0.05), 216.99 ± 44.13 versus 144.86 ± 43.98 (p < 0.05), 125.96 ± 66.76 versus 111.86 ± 47.19 (p > 0.05), and 194.30 ± 14.51 versus 168.58 ± 25.97 (p < 0.05), respectively. Conclusions: The sharp loss function could significantly improve the accuracy of radiotherapy dose prediction.